Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: implicated_in_ autism + new + protein  Related to the article below (Last Update: 12/1/2008)

 News results: Standard Version | Text Version | Image Version  
Browse Top Stories

Recent

Archives

Blogs

News Alerts News Alerts

RSS | Atom
About Feeds

Your search - implicated_in_ autism + new + protein - did not match any documents.
Suggestions:
Make sure all words are spelled correctly.
Try different keywords.
Try more general keywords.
Try fewer keywords.
Try Google Blog Search.
Also, you can browse today's headlines on the Google News homepage.
Source: Google News

 

Recent News and Articles on the Keywords: new + autism + protein  Related to the article below (Last Update: 8/5/2008)

Nastech Pharmaceutical Company Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
The Survivin protein is highly expressed in most human tumors in fetal fiddle tissue, but it?s completely acid in terminally differentiated cells. ...MRNA

ABC News
New Clues to Autism's Cause
TIME - Jul 10, 2008
Symptoms of autism typically emerge during the first five years of life ? a period when a child normally picks up language, social skills and many other new ...
Full Text Science Magazine (subscription)
all 319 news articles »
Zoobars Releases New Gluten-Free Nutrition Bars
MarketWatch - Jul 29, 2008
The large-size two-ounce bars are all gluten-free; low in sodium; a good source of protein and fiber; and contain important omega fatty acids. ...

BBC News
New light shed on health disorder
BBC News, UK - Jul 14, 2008
The autism spectrum disorder, which affects one in 10000 girls, is known to be caused by a protein called Mecp2. It blocks a gene in human DNA and prevents ...

MLive.com
Mother writes of son's autism
MLive.com, MI - Jul 10, 2008
Baker, whose practice is based in New York, also co-authored "Autism: Effective Biomedical Treatments." "Someone can recover from autism when the right ...
A2 Milk: the Solution to Lactose Intolerance, Allergies and Other ...
Natural News.com, AZ - Aug 1, 2008
Beta casein represents approximately a third of the protein content of cows' milk and consists of a good nutritional balance of amino acids. ...
Experts Recommend Gluten-, Dairy-Free Autism Diet
WCCO, MN - Jul 24, 2008
But the lack of dairy in his diet might actually be helping him grow in new ways. He is on what has become known as the autism diet, which he said does ...
New Products Let People Cut Gluten From Diet
RedOrbit, TX - Jul 30, 2008
"Certain groups of people are now trying gluten-free diets as a means of helping improve an existing condition such as autism, ADD (Attention Deficit ...
Study reveals water's role in rare autism
Scotsman, United Kingdom - Jul 12, 2008
The autism spectrum disorder is known to be caused by a protein, called Mecp2, which blocks a gene in human DNA and prevents it from functioning. ...
A2 Corp shareholders approve plan
National Business Review, New Zealand - Jul 28, 2008
... containing the A1 beta-casein protein, could lead to a range of illnesses including type 1 diabetes, heart disease, autism and schizophrenia. ...NZE:ATM
Source: Google News

The environment as an etiologic factor in autism: a new direction for research. -
EA London - Environmental Health Perspectives, 2000 - pubmedcentral.nih.gov
... Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a ... in X-linked MECP2, encoding
methyl-CpG-binding protein 2. Nat ... A new intellectual framework for psychiatry. ...

Is autism a G-alpha protein defect reversible with natural vitamin A? -
MN Megson - Medical Hypotheses, 2000 - Elsevier
... both normal mice and blind mice easily learned the new path- way ... Autism may be a
disorder linked to the disruption of the G-alpha protein and the ...

The Arg451Cys-neuroligin-3 mutation associated with autism reveals a defect in protein processing -
D Comoletti, A De Jaco, LL Jennings, RE Flynn, G … - J Neurosci, 2004 - Soc Neuroscience
... BRIEF COMMUNICATION The Arg451Cys-Neuroligin-3 Mutation Associated with Autism
Reveals a Defect in Protein Processing. Davide Comoletti ...

Autism and Autistic-like Conditions: Subclasses among Disorders of Empathy
CL Gillberg - Journal of Child Psychology and Psychiatry, 1992 - Blackwell Synergy
... In C. Gillberg (Ed.), Diagnosis and treatment of autism (pp. ... New York: Plenum Press ...
An ELISA for determination ofthe S-100 protein and the GFA protein in the CSF ...

… of 2q37. 3 deletion in autism and osteodystrophy: report of a case and of new markers for deletion … -
CC Genet - Logo, 2001 - content.karger.com
... RNA binding site of vigilin, a multi-KH-domain protein. ... patient: identification of
candidate gene for autism and of ... Bryke CR: Deletion of 2q37 - a new syndrome ...

Autism New data suggest a new hypothesis -
GR DeLong - Neurology, 1999 - AAN Enterprises
... reviewed above, may shed some new light on ... CL, Steffenburg U, Kyllerman M. Autism
in Angelman ... syndrome : evidence for myelin basic protein haploinsufficiency. ...

Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism … -
CM Durand, C Betancur, TM Boeckers, J Bockmann, P … - Nature Genetics, 2006 - nature.com
... Therefore, we hypothesize that the protein complex including ... IL Cohen and J. Tsiouris
(New York State ... Fondation France T?l?com, Cure Autism Now, Fondation de ...

Identification of the Human Cortactin-Binding Protein-2 Gene from the Autism Candidate Region at … -
J Cheung, E Petek, K Nakabayashi, LC Tsui, JB … - Genomics, 2001 - Elsevier
... didate genes for mutational analysis in autism patients. ... cDNA sequence of this putative
new gene in ... BLASTP search with the deduced protein sequence against the ...

Infantile autism and urinary excretion of peptides and protein-associated peptide complexes -
A Couteur, O Trygstad, C Evered, C Gillberg, M … - Journal of Autism and Developmental Disorders, 1988 - Springer
... New York: Pleum Press. ... psychosis and urinary excretion of peptides and protein-
associated peptide ... Journal of Autism and Developmental Disorders, 12, 3, 229-241 ...

[PDF] … for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14- … -
H Peltola, A Patja, P Leinikki, M Valle, I … - Lancet, 1998 - freenetpages.co.uk
... Autism, inflammatory bowel disease, and MMR vaccine ... Kong, Prince of Wales Hospital,
Shatin, New Territories, Hong ... activity was related to a protein of molecular ...
-

Source: Google Scholar
 

New Protein Implicated In Autism

Article Date: 27 Mar 2007 - 15:00 PDT
Autism is a common neurodevelopmental disorder characterized by severely impaired social, communicative, and behavioral functions. It is thought that genetic make-up predisposes an individual to autism, and several genes have been associated with the development of autism. Although a region of human chromosome 7 has been identified to be associated with susceptibility to autism, none of the genes in this region had been directly implicated in the disorder until researchers from the RIKEN Brain Science Institute in Japan demonstrated that mice lacking the protein CADPS2 exhibited autistic-like characteristics.

In the study, which appears online in advance of publication in the April print issue of the Journal of Clinical Investigation, Teiichi Furuichi and colleagues show that mice lacking CADPS2, which is encoded by a gene in the autism susceptibility region of human chromosome 7, had impaired social interactions (when pairs of CADPS2-deficient mice that had never met were placed together they interacted substantially less frequently than pairs of wild-type mice that had never met), hyperactivity, and decreased exploration of a new environment; all of which are characteristics of individuals with autism. Importantly, an abnormal form of CADPS2 mRNA (which is an intermediate in the conversion of the CADPS2 gene to CADPS2 protein) was detected in some individuals with autism and was never detected in their healthy immediate relatives, leading to the suggestion that defects in CADPS2 function might predispose individuals to develop autism.

Article continues below and (thank you)
 
TITLE: Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients

AUTHOR CONTACT:
Teiichi Furuichi
RIKEN Brain Science Institute, Wako, Saitama, Japan.

Contact: Karen Honey
Journal of Clinical Investigation
 

Tuberculosis: Fighting A Losing Battle - MSF Data Show Drug-Resistant TB Treatment Succeeds In Barely Half Of All Patients


Article Date: 27 Mar 2007 - 15:00 PDT
The international medical organization Doctors Without Borders/Médecins Sans Frontières (MSF) today released statistics showing that even under optimized conditions, treatment will succeed in barely more than half of patients with multi-drug resistant (MDR) Tuberculosis (TB). As insufficient research and development on new drugs and diagnostics has left health staff without the right tools to treat the disease, some patients will go on to develop extensively drug-resistant (XDR) TB regardless of the quality of care they are offered. The situation is particularly alarming when treating people co-infected with TB and HIV.

"When resistance emerges to the major TB drugs, we're forced to go back to using older, less effective ones", said Dr. Jessica Adam, a doctor in MSF's program in Uzbekistan. "This means a much longer, much more expensive treatment course that can cost up to US$15,000, and it means relying on drugs that are toxic: the side effects are simply horrible."

Since 1999, MSF has invested considerable resources and provided rigorous support to treat 570 patients with MDR TB in Armenia, Abkhazia, Georgia, Cambodia, Kenya, Thailand, Uganda, and Uzbekistan. Despite these efforts, only 55 percent of the patients completed the 18-24 month course of treatment. The remaining 45 percent died, did not improve with treatment, or defaulted because of side effects, isolation, and other difficulties in tolerating the treatment.

Diagnosing MDR-TB is also extremely difficult. Most resource-poor settings do not have access to the necessary sophisticated diagnostic equipment. But even in the best of settings that do possess the equipment, it can take up to eight weeks to obtain a result. For patients co-infected with HIV who are already ill, such delays can mean the difference between life and death.

"In places where we see a lot of HIV/AIDS, the risk of MDR-TB spreading like wildfire is a terrifying but all too likely prospect," said Dr. Liesbet Ohler, who works with MSF's program in Mathare, a slum near Nairobi, Kenya. "Treating MDR-TB and HIV simultaneously is incredibly frustrating because of drug interactions and the potential for many strong side effects, let alone the number of pills patients have to take every day. With the tools we have today, we're fighting a losing battle."

Last year's XDR epidemic in South Africa sparked international concern about the extent of the crisis and the urgency of finding solutions. Now, concrete actions need to be taken. The World Health Organization (WHO) needs to take the lead to develop new strategies against the disease.

Despite the urgency of the situation, current research efforts are not keeping pace with the need for better tests, drugs, and vaccines. An analysis conducted by MSF of the TB research and development pipeline found that none of the compounds under development today will be able to deliver the drastically shorter treatment that is needed to curb the disease. Similarly, the diagnostics under development will not be simple enough to use in resource-limited settings and will not reliably detect the disease. There is a critical funding gap for research and development for TB, with around $900 million needed annually, but only $206 million invested.

"MDR TB and now XDR TB are the tips of an iceberg of failing strategies to curb tuberculosis," said Dr. Tido von Schoen-Angerer, director of MSF's Campaign for Access to Essential Medicines. "We desperately need new tools and we need them now - we cannot just sit and wait. There is no quick, ready-made solution - but that is not an excuse not to act. One important step is to have all TB drugs in development tested in trials with MDR patients: this would be a quicker way to see whether new compounds are efficacious for patients with regular TB and give those with MDR a chance for better treatment," he said." At the moment, only one company has stated that it is planning to conduct an MDR trial while others sit on the fence. WHO needs to ensure that these trials will happen."

MSF is currently treating over 20,000 people with TB in more than 40 countries.

http://www.doctorswithoutborders.org
 
Google
Web www.iconocast.com
 
 
Source for News : URL: http://www.medicalnewstoday.com and Reuters
Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast